UroGen Pharma Ltd. Files 8-K: Material Agreement & Equity Sales

TL;DR

UroGen Pharma inked a big deal and sold some stock on Feb 14th.

AI Summary

UroGen Pharma Ltd. announced on February 14, 2025, that it entered into a material definitive agreement and also reported unregistered sales of equity securities. The company is incorporated in Israel and its principal executive offices are located in Princeton, New Jersey.

Why It Matters

This filing indicates significant corporate actions, including a new material agreement and equity transactions, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing mentions both a material definitive agreement and unregistered sales of equity, which can introduce complexities and potential risks related to financing and shareholder dilution.

Key Numbers

• 001-38079 — SEC File Number (Identifies UroGen Pharma's filing with the SEC.)
• 98-1460746 — IRS Employer Identification No. (UroGen Pharma's tax identification number.)

Key Players & Entities

• UroGen Pharma Ltd. (company) — Registrant
• February 14, 2025 (date) — Date of earliest event reported
• Princeton, New Jersey (location) — Address of principal executive offices
• Israel (location) — State or other jurisdiction of incorporation

FAQ

From the Filing

0001193125-25-030143.txt : 20250220 0001193125-25-030143.hdr.sgml : 20250220 20250220080511 ACCESSION NUMBER: 0001193125-25-030143 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250214 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities FILED AS OF DATE: 20250220 DATE AS OF CHANGE: 20250220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 25643341 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 8-K 1 d897858d8k.htm 8-K 8-K false 0001668243 0001668243 2025-02-14 2025-02-14     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025     UROGEN PHARMA LTD. (Exact name of registrant as specified in its charter)       Israel   001-38079   98-1460746 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   400 Alexander Park Drive , 4th Floor Princeton , New Jersey   08540 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: +1 (646) 768-9780     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Ordinary Shares, par value NIS0.01 per share   URGN   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01 Entry into a Material Definitive Agreement. On February 14, 2025 (the “Closing Date”), UroGen Pharma Ltd. (the “Company”) and UroGen Pharma, Inc. (“Purchaser”) entered into an Asset Purchase Agreement (the “Agreement”) with IconOVir Bio, Inc. (“IconOVir”), pursuant to which Purchaser purchased and acquired certain assets of IconOVir (the “Transferred Assets”), including the product candidate ICVB-1042 and certain contracts, intellectual property rights, regulatory applications, submissions and registrations, and data and other rights related thereto, and assumed certain liabilities and obligations of IconOVir arising under certain contracts